Nebraska Hematology-Oncology
In research, Nebraska Hematology-Oncology stands highest in Medicine (#8,092 of 17,978 worldwide) and Health Sciences (#9,628 of 20,462 worldwide), over all time.
- World rank, all time
- #23,646 of 42,892
- Rank in United States
- #5,087 of 8,685
- Research works
- 253 ▼ 66% vs 2013–17
- Citations
- 8.6k 33.9 per fractional work
- Top-10% rate
- 18.0% record average 16.5%
- Open access
- 16% world 28%
What is Nebraska Hematology-Oncology known for in research?
The fields where it stands highest, over all time, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works |
|---|---|---|---|---|
| MedicineField | #8,092 of 17,978 | 20.1% | 167 | |
| Health SciencesDomain | #9,628 of 20,462 | 20.3% | 182 |
Each strip is that field’s whole ranked pool, with the notch where Nebraska Hematology-Oncology sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Veterinary, 35.6×. Every wedge is a field page.
Which keywords describe research at Nebraska Hematology-Oncology?
By fractional works in all years, weighted toward what it does more of than the world: Chemotherapy, Inflammation, Epidemiology, Immunotherapy, Guidelines, Neoadjuvant Therapy, Molecular Characterization and Diagnosis.
- Immunosuppressive Drugs
- Transplantation
- Rituximab
- Tumor Microenvironment
- Mesenchymal Stem Cells
- Cardiovascular Risk
- Complications
- Clinical Practice Guidelines
- Graft Survival
- Surgical Management
- Global Burden
- Bladder Cancer
- Cardiovascular Disease
- Risk Factors
- Molecular Characterization
- Neoadjuvant Therapy
- Diagnosis
- Guidelines
- Immunotherapy
- Inflammation
- Epidemiology
- Chemotherapy
- Oxidative Stress
- Treatment
- Cancer
- Quality of Life
- Prognostic Factors
- Management
- Urothelial Carcinoma
- Cystectomy
- Heart Failure
- Magnetic Resonance Imaging
- Genetic Mutations
- Mortality
- Autoantibodies
- Immunosuppressive Therapy
- Hematopoietic Stem Cells
- Clinical Outcomes
- Targeted Therapy
- Liver Transplantation
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Epidemiology21▲ 2.1×78 topics
- Inflammation18▲ 3.1×54 topics
- Chemotherapy15▲ 8.4×22 topics
- Immunotherapy11▲ 6.8×16 topics
- Oxidative Stress10▲ 2.2×33 topics
- Guidelines10▲ 8.1×11 topics
- Treatment9▲ 2.6×31 topics
- Diagnosis9▲ 3.3×28 topics
- Cancer8▲ 2.2×27 topics
- Neoadjuvant Therapy8▲ 14×5 topics
- Quality of Life7▲ 1.99×30 topics
- Molecular Characterization6▲ 14×5 topics
- Prognostic Factors6▲ 5.5×13 topics
- Risk Factors6▲ 2.4×20 topics
- Management6▲ 3.1×18 topics
- Cardiovascular Disease6▲ 2.1×22 topics
- Urothelial Carcinoma5▲ 48×2 topics
- Bladder Cancer5▲ 55×1 topic
- Cystectomy5▲ 55×1 topic
- Global Burden5▲ 3.6×9 topics
- Heart Failure5▲ 4.2×11 topics
- Surgical Management5▲ 4.2×16 topics
- Magnetic Resonance Imaging5▲ 4.9×7 topics
- Graft Survival4▲ 17×3 topics
- Genetic Mutations4▲ 3.3×15 topics
- Clinical Practice Guidelines4▲ 3.0×13 topics
- Mortality4▲ 3.4×9 topics
- Complications4▲ 3.2×12 topics
- Autoantibodies4▲ 6.7×5 topics
- Cardiovascular Risk4▲ 4.3×6 topics
- Immunosuppressive Therapy4▲ 7.8×6 topics
- Mesenchymal Stem Cells4▲ 13×3 topics
- Hematopoietic Stem Cells4▲ 14×3 topics
- Tumor Microenvironment4▲ 4.0×6 topics
- Clinical Outcomes3▲ 6.7×4 topics
- Rituximab3▲ 7.8×3 topics
- Targeted Therapy3▲ 5.5×5 topics
- Transplantation3▲ 10×4 topics
- Liver Transplantation3▲ 7.3×4 topics
- Immunosuppressive Drugs3▲ 16×2 topics
Which research topics does Nebraska Hematology-Oncology publish most on?
By volume in 2022–2025: Cancer and Skin Lesions, CNS Lymphoma Diagnosis and Treatment, Chronic Lymphocytic Leukemia Research and Nonmelanoma Skin Cancer Studies.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer and Skin Lesions Dermatology 0 works
- 2 CNS Lymphoma Diagnosis and Treatment Neurology 0 works
- 3 Chronic Lymphocytic Leukemia Research Genetics 0 works
- 4 Nonmelanoma Skin Cancer Studies Epidemiology 0 works
- 5 Autoimmune Neurological Disorders and Treatments Neurology 0 works
- 6 Cytomegalovirus and herpesvirus research Epidemiology 0 works
- 7 Infectious Diseases and Mycology Small Animals 0 works
- 8 Diabetes Treatment and Management Endocrinology, Diabetes and Metabolism 0 works
- 9 Peripheral Artery Disease Management Surgery 0 works
- 10 Prenatal Screening and Diagnostics Pediatrics, Perinatology and Child Health 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Nebraska Hematology-Oncology's research output changed?
Output in 2018–2022 was 66% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Lincoln
- University of Nebraska–Lincoln
- Entrepreneurial Ecosystems
- University of Nebraska System
- Pacific Engineering (United States)
- Nebraska Wesleyan University
- Nebraska Game and Parks Commission
- Bryan Health
- J.A. Woollam Company (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.